pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,742 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1560Endpoints1219BioSpace559Fierce Biotech555BioPharma Dive464raps192onclive165fda recalls
therapy area
allOncology10376Rare Disease2719Immunology2442Cardiology2281Hematology1880Pulmonology1872Vaccines
  • Eli Lilly signals entry into aesthetics market with plans to acquire skin, body and hair treatments
    Eli Lilly is indicating an interest in expanding into the aesthetics sector, according to a recent job posting. The company appears to be seeking opportunities to add products that address skin agi…
    Endpoints · 18d agoNeutral↗ source
  • Researchers claim small molecules could reprogram cells, hinting at a future anti‑aging pill
    Scientists have identified tiny compounds that appear to reset cells to a more youthful condition, according to a recent report featuring David Sinclair’s lab. The molecules work by altering cellul…
    Endpoints · 18d agoPositive↗ source
← prev
page 8 of 70
next →
102
fda medwatch93
globenewswire health73
fda press54
1641
Psychiatry & CNS1107
Ophthalmology849
Endocrinology & Metabolism687
Pain654
Nephrology634
Regeneron explores pairing its obesity drug with lipid-lowering therapy to differentiate in crowded GLP-1 market
The pipeline of GLP-1 based medicines is delivering increasingly strong weight-loss results, prompting many companies to seek ways to stand out as the market fills. Regeneron said it is looking at…
Endpoints · 19d agoPositive↗ source
  • Moderna appoints former executive Juan Andres as COO as Neurocrine reshuffles leadership; Pharming CEO steps down after board dispute
    Juan Andres, a former Moderna executive, will return from retirement to assume the role of chief operating officer on Oct. 5. His deep familiarity with the company is seen as valuable as Moderna ad…
    Endpoints · 19d agoNeutral↗ source
  • FDA device center outlines FY 2027 guidance agenda, focusing on AI devices and change control plans
    The FDA's Center for Devices and Radiological Health announced its guidance priorities for fiscal year 2027 on Oct 1. The top items are finalizing guidance on artificial intelligence‑enabled medic…
    raps · 19d agoRegulatoryNeutral↗ source
  • Summit Therapeutics partners with AstraZeneca and Daiichi Sankyo on cancer trial; Eccogene hits $50 million milestone
    Summit Therapeutics announced a partnership with AstraZeneca and Daiichi Sankyo to evaluate its Trop-2‑directed antibody‑drug conjugate in a clinical trial. The collaboration will involve joint de…
    Endpoints · 18d agoDealPositive↗ source
  • Draeger recalls VentStar Resus Neo hoses over crack risk
    Draeger has issued a Class I recall for its VentStar Resus Neo breathing circuit hoses after discovering that some hoses can develop cracks or become detached. The company sent a letter to custome…
    fda medwatch · 19d agoCRLNegative↗ source
  • FDA device center outlines FY 2027 guidance plan, targeting AI-enabled devices and change-control plans
    On Oct 1, the FDA’s Center for Devices and Radiological Health announced its guidance agenda for fiscal year 2027. The top priority is finalizing guidance for artificial intelligence-enabled medic…
    raps · 19d agoRegulatoryNeutral↗ source
  • Sanofi to pay $1 billion upfront to expand antibody partnership with Regeneron
    Sanofi announced it will provide Regeneron with a $1 billion upfront payment to broaden their existing antibody collaboration. The agreement is timed as the patent protection for Dupixent, the joi…
    Endpoints · 20d agoDealNeutral↗ source
  • Devoted Health secures $1.2 billion in new funding to fuel senior member growth
    Devoted Health, a Medicare Advantage insurer and medical group, announced a fresh capital injection of nearly $1.2 billion. The financing round includes a $555 million Series G investment along wi…
    Endpoints · 19d agoDealPositive↗ source
  • HHS unveils ARPA-H SURPASS program to accelerate clinical trial design
    On Oct 1, 2026 the U.S. Department of Health and Human Services announced a new initiative under the Advanced Research Projects Agency for Health. The initiative, named the Simulation-augmented, R…
    raps · 20d agoRegulatoryNeutral↗ source
  • EU Council adopts new pharma package to modernize drug legislation
    The Council of the European Union has approved a comprehensive "pharma package" of rules aimed at updating the regulatory framework for medicines across the bloc. The new legislation seeks to stre…
    raps · 20d agoRegulatoryNeutral↗ source
  • United Therapeutics wins Delaware court case; BMS secures pediatric approval for Camzyos
    United Therapeutics secured a legal victory in a federal court in Delaware, with the judge ruling in the company's favor. The decision marks a notable win for the biotech firm, though the specific…
    Endpoints · 19d agoApprovalNeutral↗ source
  • Eli Lilly ends partnership with Foghorn Therapeutics, prompting 40% staff cut at biotech
    Eli Lilly announced it is withdrawing from its collaboration with Foghorn Therapeutics on a synthetic lethality drug program. Following the pullback, Foghorn said it will cut roughly 40% of its wo…
    Endpoints · 19d agoDealNegative↗ source
  • Regeneron antibody restores muscle loss in patients after stopping Wegovy, mid-stage data show
    Regeneron presented new mid-stage data at the European Association for the Study of Diabetes (EASD) meeting in Milan showing its investigational antibody can help patients with obesity recover musc…
    Endpoints · 19d agoPositive readoutPositive↗ source
  • Kallyope rebrands as TriGemX Bio, secures $94M to fund Phase 3 migraine trial
    Kallyope, a New York City drug developer, announced it is changing its name to TriGemX Bio as it narrows its pipeline to migraine. The rebrand follows a recent partnership with Novo on an obesity…
    Endpoints · 20d agoDealPositive↗ source
  • Boehringer's obesity drug shows up to 9.8% weight loss in diabetes patients but lags behind competitors
    Boehringer Ingelheim presented data at the European Association for the Study of Diabetes (EASD) meeting in Milan, showing its lead obesity candidate achieved up to 9.8% weight reduction in a late-…
    Endpoints · 20d agoNegative readoutNeutral↗ source
  • ICMRA urges cut to animal testing while HHS launches ARPA-H SURPASS program to accelerate clinical trials
    International Coalition of Medicines Regulatory Authorities released a joint statement urging drug makers and national control labs to cut back on animal testing throughout a medicine’s development…
    raps · 20d agoRegulatoryNeutral↗ source
  • HHS unveils ARPA-H SURPASS program to accelerate clinical trial design
    The U.S. Department of Health and Human Services announced a new initiative under ARPA-H called the Simulation‑augmented, Real‑time Platform Adaptive Seamless Trials (SURPASS) program. SURPASS is…
    raps · 20d agoRegulatoryPositive↗ source
  • Study finds AI may be driving up healthcare costs
    A recent analysis by the Blue Cross Blue Shield Association challenges the common belief that artificial intelligence will lower healthcare spending. The report argues that, instead of delivering…
    Endpoints · 19d agoNegative↗ source
  • Anthropic AI reports first scientific discovery: new enzyme system
    Anthropic announced that its Claude AI system has identified a previously unknown enzyme system, marking the company's first reported scientific discovery. The life sciences team, led by Eric Kaud…
    Endpoints · 19d agoPositive↗ source
  • Parakeet Health secures $10 million to expand AI-driven patient outreach platform
    Parakeet Health, a health-tech startup, announced it has raised $10 million in funding, according to Endpoints News. The capital will be used to scale its AI-powered platform that contacts patient…
    Endpoints · 19d agoDealPositive↗ source
  • House lawmakers hear mixed views on credentialing for psychedelic providers
    As psychedelic medicines move closer to market, two members of the U.S. House are outlining how the drugs might be rolled out and what accompanying legislation could look like. The focus of their…
    Endpoints · 20d agoRegulatoryNeutral↗ source
  • Merck reports positive mid-stage results for Prometheus' tulisokibart in painful skin disease
    Merck presented new data from a mid-stage trial of tulisokibart, a drug acquired through its $10.8 billion purchase of Prometheus Biosciences. The trial evaluated multiple dose levels in patients…
    Endpoints · 21d agoPositive readoutPositive↗ source
  • Patient death raises safety concerns before Bristol Myers lung drug readout
    A patient died from a fatal liver injury while taking part in a trial of Bristol Myers Squibb's lung disease candidate. The company disclosed the incident in a May amendment to its trial documents…
    Endpoints · 20d agoNegative↗ source